|
1
|
Rowley JD: Identificaton of a
translocation with quinacrine fluorescence in a patient with acute
leukemia. Ann Genet. 16:109–112. 1973.PubMed/NCBI
|
|
2
|
Yergeau DA, Hetherington CJ, Wang Q, Zhang
P, Sharpe AH, Binder M, Marín-Padilla M, Tenen DG, Speck NA and
Zhang DE: Embryonic lethality and impairment of haematopoiesis in
mice heterozygous for an AML1-ETO fusion gene. Nat Genet.
15:303–306. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Higuchi M, O'Brien D, Kumaravelu P, Lenny
N, Yeoh EJ and Downing JR: Expression of a conditional AML1-ETO
oncogene bypasses embryonic lethality and establishes a murine
model of human t(8;21) acute myeloid leukemia. Cancer Cell.
1:63–74. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rhoades KL, Hetherington CJ, Harakawa N,
Yergeau DA, Zhou L, Liu LQ, Little MT, Tenen DG and Zhang DE and
Zhang DE: Analysis of the role of AML1-ETO in leukemogenesis, using
an inducible transgenic mouse model. Blood. 96:2108–2115.
2000.PubMed/NCBI
|
|
5
|
Jiao B, Wu CF, Liang Y, Chen HM, Xiong SM,
Chen B, Shi JY, Wang YY, Wang JH, Chen Y, et al: AML1-ETO9a is
correlated with C-KIT overexpression/mutations and indicates poor
disease outcome in t(8;21) acute myeloid leukemia-M2. Leukemia.
23:1598–1604. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Paschka P, Marcucci G, Ruppert AS, Mrózek
K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW,
Carroll AJ, et al Cancer and Leukemia Group B: Adverse prognostic
significance of KIT mutations in adult acute myeloid leukemia with
inv(16) and t(8;21): A Cancer and Leukemia Group B Study. J Clin
Oncol. 24:3904–3911. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schnittger S, Kohl TM, Haferlach T, Kern
W, Hiddemann W, Spiekermann K and Schoch C: KIT-D816 mutations in
AML1-ETO-positive AML are associated with impaired event-free and
overall survival. Blood. 107:1791–1799. 2006. View Article : Google Scholar
|
|
8
|
Wang YY, Zhao LJ, Wu CF, Liu P, Shi L,
Liang Y, Xiong SM, Mi JQ, Chen Z, Ren R, et al: C-KIT mutation
cooperates with full-length AML1-ETO to induce acute myeloid
leukemia in mice. Proc Natl Acad Sci USA. 108:2450–2455. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nick HJ, Kim HG, Chang CW, Harris KW,
Reddy V and Klug CA: Distinct classes of c-Kit-activating mutations
differ in their ability to promote RUNX1-ETO-associated acute
myeloid leukemia. Blood. 119:1522–1531. 2012. View Article : Google Scholar :
|
|
10
|
Wichmann C, Quagliano-Lo Coco I, Yildiz Ö,
Chen-Wichmann L, Weber H, Syzonenko T, Döring C, Brendel C,
Ponnusamy K, Kinner A, et al: Activating c-KIT mutations confer
oncogenic cooperativity and rescue RUNX1/ETO-induced DNA damage and
apoptosis in human primary CD34+ hematopoietic
progenitors. Leukemia. 29:279–289. 2015. View Article : Google Scholar
|
|
11
|
Zhang MY, Zheng CY, Zou MM, Zhu JW, Zhang
Y, Wang J, Liu CF, Li QF, Xiao ZC, Li S, et al: Lamotrigine
attenuates deficits in synaptic plasticity and accumulation of
amyloid plaques in APP/PS1 transgenic mice. Neurobiol Aging.
35:2713–2725. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hansel DE, Rahman A, Wehner S, Herzog V,
Yeo CJ and Maitra A: Increased expression and processing of the
Alzheimer amyloid precursor protein in pancreatic cancer may
influence cellular proliferation. Cancer Res. 63:7032–7037.
2003.PubMed/NCBI
|
|
13
|
Ko SY, Lin SC, Chang KW, Wong YK, Liu CJ,
Chi CW and Liu TY: Increased expression of amyloid precursor
protein in oral squamous cell carcinoma. Int J Cancer. 111:727–732.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Krause K, Karger S, Sheu SY, Aigner T,
Kursawe R, Gimm O, Schmid KW, Dralle H and Fuhrer D: Evidence for a
role of the amyloid precursor protein in thyroid carcinogenesis. J
Endocrinol. 198:291–299. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Takayama K, Tsutsumi S, Suzuki T,
Horie-Inoue K, Ikeda K, Kaneshiro K, Fujimura T, Kumagai J, Urano
T, Sakaki Y, et al: Amyloid precursor protein is a primary androgen
target gene that promotes prostate cancer growth. Cancer Res.
69:137–142. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baldus CD, Liyanarachchi S, Mrózek K, Auer
H, Tanner SM, Guimond M, Ruppert AS, Mohamed N, Davuluri RV,
Caligiuri MA, et al: Acute myeloid leukemia with complex karyotypes
and abnormal chromosome 21: Amplification discloses overexpression
of APP, ETS2, and ERG genes. Proc Natl Acad Sci USA. 101:3915–3920.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang W, Meng FY, Huang ZF, Huang M and Liu
LX: Expression and role of amyloid precrusor protein gene in acute
myeloid leukemia. Chin J Hematol. 31:309–314. 2010.In Chinese.
|
|
18
|
Jiang L, Yu G, Meng W, Wang Z, Meng F and
Ma W: Overexpression of amyloid precursor protein in acute myeloid
leukemia enhances extramedullary infiltration by MMP-2. Tumour
Biol. 34:629–636. 2013. View Article : Google Scholar
|
|
19
|
Larizza L, Magnani I and Beghini A: The
Kasumi-1 cell line: A t(8;21)-kit mutant model for acute myeloid
leukemia. Leuk Lymphoma. 46:247–255. 2005. View Article : Google Scholar
|
|
20
|
Pulikkan JA, Madera D, Xue L, Bradley P,
Landrette SF, Kuo YH, Abbas S, Zhu LJ, Valk P and Castilla LH:
Thrombopoietin/MPL participates in initiating and maintaining
RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling. Blood.
120:868–879. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kumar A, Fernandez-Capetillo O and Carrera
AC: Nuclear phosphoinositide 3-kinase β controls double-strand
break DNA repair. Proc Natl Acad Sci USA. 107:7491–7496. 2010.
View Article : Google Scholar
|
|
22
|
Sheng S, Qiao M and Pardee AB: Metastasis
and AKT activation. J Cell Physiol. 218:451–454. 2009. View Article : Google Scholar
|
|
23
|
Wang L, Zhao WL, Yan JS, Liu P, Sun HP,
Zhou GB, Weng ZY, Wu WL, Weng XQ, Sun XJ, et al: Eriocalyxin B
induces apoptosis of t(8;21) leukemia cells through NF-κB and MAPK
signaling pathways and triggers degradation of AML1-ETO oncoprotein
in a caspase-3-dependent manner. Cell Death Differ. 14:306–317.
2007. View Article : Google Scholar
|
|
24
|
Krejci O, Wunderlich M, Geiger H, Chou FS,
Schleimer D, Jansen M, Andreassen PR and Mulloy JC: p53 signaling
in response to increased DNA damage sensitizes AML1-ETO cells to
stress-induced death. Blood. 111:2190–2199. 2008. View Article : Google Scholar
|
|
25
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte
G, Mazzarino MC, et al: Mutations and deregulation of
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy
response. Oncotarget. 3:954–987. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hart JR and Vogt PK: Phosphorylation of
AKT: A mutational analysis. Oncotarget. 2:467–476. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Datta SR, Dudek H, Tao X, Masters S, Fu H,
Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples
survival signals to the cell-intrinsic death machinery. Cell.
91:231–241. 1997. View Article : Google Scholar : PubMed/NCBI
|
